In this sense, even though AK-1 (IC50 = 12.5 μM) is more potent than AK-7 (IC50 = 15.5 μM), it lacks blood–brain barrier (BBB) permeability, a crucial characteristic for the treatment of neurodegenerative diseases [102]. Here, AK1 is linked to neurodegenerative disease.